In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization
- PMID: 33197352
- DOI: 10.7326/ACPJ202011170-051
In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization
Abstract
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. 32865377.
Comment on
-
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. N Engl J Med. 2020. PMID: 32865377 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous